<DOC>
	<DOCNO>NCT02034162</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety mebendazole compare placebo pediatric participant Helminth infection .</brief_summary>
	<brief_title>A Study Assess Efficacy Safety Mebendazole Treatment Helminth Infections Pediatric Participants</brief_title>
	<detailed_description>This double-blind ( neither physician participant know treatment participant receives ) , randomize ( study drug assign chance ) , multi-center , parallel-group study ( group participant treat time ) evaluate efficacy safety mebendazole ( drug currently investigate Helminth gastrointestinal infection ) compare placebo ( inactive substance compare drug test whether drug real effect clinical trial ) child ( include pre-school school-aged child ) Helminth infection . The study consist 3 phase : screening phase , double-blind treatment phase , post-treatment ( follow-up ) phase . A pharmacokinetic ( explores drug body ) open-label substudy ( asks separate research question parent study use participant population contribute parent study 's objective ) include parent study measure level mebendazole blood . Safety assessment perform throughout study . Each participant take part study approximately 30 day .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Helminthiasis</mesh_term>
	<mesh_term>Mebendazole</mesh_term>
	<mesh_term>Piperazine</mesh_term>
	<mesh_term>Piperazine citrate</mesh_term>
	<criteria>Female participant &gt; =9 year old must negative urine pregnancy test screening time randomization Participants must otherwise healthy child , base medical history , physical examination , vital sign , hemoglobin , concomitant medication Participants &gt; =3 year age must teeth able chew Participant must available return study site visit , include followup visit Parent ( ) /guardians participant ( legallyaccepted representative ) must sign informed consent document indicate understand purpose procedure require study willing child participate study Children 6 year age old ask assent ( agree ) participation use appropriate language level understanding ; assent document Participant active diarrhea ( defined passage 3 loose liquid stool per day ) screening time randomization Participant significant medical disorder , participant difficulty chew swallow Participant significant anemia ( &lt; 8 g/dL ) Participant significant wasting ( great 2 standard deviation mean World Health Organization [ WHO ] Child Growth Standards weightforheight body mass index ) Participant know hypersensitivity mebendazole , inert ingredient chewable formulation Participant preplanned surgery/procedures would interfere conduct study course study Participants receive investigational drug ( include vaccine ) use investigational medical device within 30 day plan start treatment , currently enrol investigational study Employees investigator study site , direct involvement propose study study direction investigator study site , well family member employee investigator Participant take form medication contain mebendazole treatment soil transmit helminth infection within 30 day entry study</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Helminth infection</keyword>
	<keyword>Helminths</keyword>
	<keyword>Pediatric</keyword>
	<keyword>Preschool age</keyword>
	<keyword>School age</keyword>
	<keyword>Mebendazole</keyword>
	<keyword>Vermox</keyword>
	<keyword>Placebo</keyword>
</DOC>